MiLOC is the holding company for a pharmaceutical and healthcare service group based primarily in Hong Kong, Macau and China. Its three major operating subsidiaries are MiLOC Biotechnology, MiLOC
Pharmaceutical and MiLOC Medical. The group has identified three major business development opportunities relating to traditional Chinese medicine (TCM). These are the research and development of TCM for pandemic diseases; sale and distribution of TCM, and the development of a nationwide network of modernised TCM clinics and hospitals.
In China, Hong Kong and Macau, MiLOC Group will begin acquisition and/or collaboration to setup MiLOC Group’s TCM Premiere Health Club (TCM-PHC). This network will provide premium services, and make prescriptions available for sale. The company is chaired by founder Chow Fung Ching, a registered TCM practitioner.
Mazars LLP acted as reporting accountants on the transaction, led by Richard Metcalfe, supported by Graham Duncan and May Ho. ZAI Corporate Finance is the company's nominated adviser and broker.